4th Annual Pharmacovigilance & Drug Safety Summit

Excelling at Seizing Opportunities and Overcoming Challenges in the Contemporary Pharmacovigilance Landscape

24 — 25 March, 2022 HYBRID - Berlin/Virtual

The event has already occured.

Key facts

Date: 24 — 25 March, 2022

Place: HYBRID - Berlin/Virtual

Conference Overview

The 4th edition of the Pharmacovigilance & Drug Safety Summit by GlobalBSG will bring more interaction, stronger networking, and a deeper exchange of expertise in 2022! 

Field professionals from leading pharmaceutical companies will gather to listen to well-endorsed speakers talking about the 2022 updates on pharmacovigilance and drug safety. 

Enlarging the information flow in contemporary challenges and opportunities in clinical trials, novel therapeutics development, rising demand for drugs, regulatory compliance, benefit-risk assessment, real-world evidence, and many other trending topics; business leaders will be a part of a valuable exchange that helps them reach their business goals by learning from the experiences of each other. 

This event will include a great variety of case studies, panel discussions, keynote speeches, and interactive Q&A sessions focusing on the most significant topics in the pharmacovigilance sector such as modifications to the EU guidance on good pharmacovigilance practices, vaccines in pharmacovigilance, artificial intelligence signal detection, data management, risk minimization tools, and integrated software. 

This edition of the summit takes a hybrid approach, allowing speakers, delegates, and sponsors to meet in person and virtually, which gives us the great flexibility to include field leaders from all over the world regardless of the travel restrictions. 

GlobalBSG serves the overarching need of the pharma experts to stay updated, informed, and connected in this important era for the sector, and invites you to join us at this event! 

Key topics

  • Improved Use of Patient Experience Data Through Improved BR Evaluation 
  • The Rise of Machine tools in Aggregate Reports and Signal Management
  • Finding the Right Balance in Quality Management Systems
  • Risk Minimisation: Ways of Integrating Different Pieces of Software for Signalling, Tracking, Auditing
  • Technological Trends in Pharmacovigilance: Machine Learning, Innovation, AI
  • Real-World Evidence for Risk Management & Application of Data Analytics 
  • COVID-19: Opportunities and Challenges in Vaccine Development 
  • Value of Audits for Process Improvements and Achieving Successful Inspection Outcomes

Who should attend

CEOs / Presidents / MDs, CCOs/CMOs/CDOs, Chief Executives, Directors, Vice Presidents, Department Heads, Leaders, and Managers specialising in:

  • Assurance & Compliance
  • Quality Assurance
  • Quality Control
  • Data Analysis
  • Pharmacovigilance
  • Pharmacology
  • Pharmacoepidemiology
  • Epidemiology
  • Medical Information
  • Health Outcomes
  • PSUR/PBRER
  • Clinical Data Management
  • MedDRA
  • PV Agreements
  • PASS/PAES
  • PSMF
  • CAPA
  • QPPV
  • Medical Affairs
  • Adverse Drug Reactions
  • Drug/Product Safety
  • Drug Development
  • RMPs
  • GPvP
  • ICH-GCP
  • Clinical Pharmacology
  • Clinical Safety
  • Clinical Trials
  • Clinical Trial Management
  • Clinical Development
  • Clinical Research
  • Risk Management
  • Research & Development
  • Patient Safety
  • Signal Detection
  • Signal Management
  • Safety Surveillance
  • Safety Databases
  • Safety Evaluation
  • Outcome Research
  • Regulatory Affairs and Compliance
  • Data management and data mining
  • Benefit-Risk Assessment
  • Regulatory Submissions
  • PV Governance
  • Safety Management
  • Pharmacovigilance Operations
  • PV Inspection and Audit Readiness
  • Patient Support Programs
  • Medical Safety
  • Medical Product Safety Assessment
  • Phase IV/Postmarketing Safety

Target audience

  • International and regional health authorities and regulators
  • Pharmaceutical, Vaccines, & Biotechnology companies
  • Clinical Research Organization (CRO) service providers
  • Business Process Outsourcing (BPO) service providers
  • Risk Management Software developers
  • Pharmacovigilance Audit Firm
  • Pharmacovigilance consultancy service providers
  • Contract Research Organisations
  • Adverse Event/Case Management Service Providers
  • Safety Database Providers for Case Management
  • Healthcare/Pharmacovigilance Consultants
  • Healthcare Translation Agencies
  • Technology Vendors/Portal Service Providers

Event Speakers

Yvonne Nanciu

Country Head Pharmacovigilance Germany

Bayer

Michael Glaser

Safety Innovation Technology Director

GSK

Stephanie Tcherny-Lessenot

Head of Epidemiology and Benefit-Risk Evaluation

Sanofi

Michael von Forstner

Head of Patient Safety

Biogen

Raj Bhogal

Senior Director, Head of R&D Audits & Inspections, Global Quality

Jazz Pharmaceuticals

Robert Di Giovanni

Global Patient Safety Lead

Novartis

Andrea Oliva

Head of Pharmacovigilance

Viatris

Giovanni Furlan

Safety Risk Lead & Director

Pfizer

Mayada Alkhakany

Senior Global Non-Trial Activities Manager

Boehringer Ingelheim

Raghda Mohamed

Patient Safety Cluster Lead - Middle East and Turkey

Takeda

Danielle Abatemarco

Associate Director, PV Strategy, Planning and Execution

BeiGene

Michael Braun-Boghos

Senior Director Safety Strategy

Oracle

Siva Kumar Buddha

Global Pharmacovigilance Physician Senior Manager

Teva

Jesper Borgstrøm

Advanced Advisory Consultant

NNIT

Hadir Rostom

Consultant

WHO

Helen Zhan

Senior Director, Operations & Quality Management System

Beigene

Mark Perrott

Founder and Manager

Axian Consulting

Companies attending the conference

Subscribe to our newsletter

Receive exclusive offers & the latest news on our events and services.